Global Blood Therapeutics, Inc (GBT)

New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

The bears pounced on the company despite a first-quarter bottom-line beat.

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor conferences: Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, at 2:40 p.m. P.T.; andRBC Capital Markets 2022 Global Healthcare Conference in New York, NY on Wednesday, May 18, at 9:00 a.m. E.T. The fireside chats will be webcast live from GBT’s website at w

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2022, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 46,400 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employe

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

GBT earnings call for the period ending March 31, 2022.

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors ...

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 years and over Reinitiated GBT601 Phase 1 trial in sickle cell disease (SCD) patients to study 150 mg daily dose; on track to initiate Phase 2/3 trial by mid-year Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 20

Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate GovernanceSOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environmental, social and governance (ESG) report, which

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. ...

How far off is BMTC Group Inc. ( TSE:GBT ) from its intrinsic value? Using the most recent financial data, we'll take a...

(TSX: GBT) The Company announces that it has received the required regulatory approvals to renew its normal course issuer bid to acquire for cancellation Common Shares listed on the Toronto Stock Exchange (the "TSX") for the period between April 15th, 2022 and April 14th, 2023, at the latest. The Company's previous normal course issuer bid ends April 14th, 2022. Pursuant to its renewed normal course issuer bid, the Company intends to acquire, through the facilities of the TSX and through alterna

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel Villepinte, April 6, 2022 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and medical imaging solutions, has announced the appointment of Charlotte Bamière, General Counsel, to the Executive Committee. Charlotte Bamière has contributed to the development of Guerbet’s legal function since joining the Group in 2011. In 2015, Charlotte Bamière and her team played a crucial par

Last year was marked by strong GDP and corporate earnings growth as the economy reopened and the workforce got back to work post-lockdowns. Stocks rose, too, reaching record highs by year’s end. That all crashed to a halt this past January. This year got started with a steady drop across the main equities indexes, especially on the tech-heavy NASDAQ. The markets troughed, deep in correction territory, in mid-March. Since then they have rebounded, and the stock market losses have moderated. Year-

Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based co

Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA Priority Review granted by US-FDAMarch 28, 2022 Villepinte (France), March 29 2022 – Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administ

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T. The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event. About Global Blood Therapeu

Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

GBT earnings call for the period ending December 31, 2021.

Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD ...

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Core AlphaDEX Fund ETF (FYX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.52 per unit.

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the ...